TTRNA-xALT

Phase 1Biologic

UUniversity of Florida

TTRNA-xALT is one of 10 biologic programs targeting Recurrent Group 3 Medulloblastoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Group 3 MedulloblastomaRecruiting

OligodendrogliomaActive, not recruiting

Recurrent Group 3 MedulloblastomaPhase 1

Recruiting

OligodendrogliomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Oligodendroglioma

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Verzenio

1 3

L19TNF

PPhilogen S.p.A.

Phase 2

1 4

Tislelizumab Plus Bevacizumab

HHenan Provincial People's Hospital

Phase 2

1 5

Fluzone

Voranigo

TTRNA-xALT

UUniversity of Florida

Phase 1

1 8

TTRNA-DC Vaccines With GM-CSF

UUniversity of Florida

Phase 1

1 9

Matulane

LLeadiant Biosciences, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Active, not recruiting

Oligodendroglioma

NCT06254326

Q4 2028

Phase 1Recruiting

Recurrent Group 3 Medulloblastoma

NCT06514898

Clinical

Trials by Indication[1]

Glioma2 trials

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

Terminated·UUniversity of Florida·Phase 1·NCT03396575·11 enrolled

Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas

Terminated·UUniversity of Florida·Phase 1·NCT03334305·18 enrolled

Oligodendroglioma1 trial

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

Active, not recruiting·UUniversity of Florida·Phase 1·NCT06254326·12 enrolled

Medulloblastoma1 trial

Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive T Cell Therapy During Recover From Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation

Completed·UUniversity of Florida·Phase 2·NCT01326104·26 enrolled

Recurrent Group 3 Medulloblastoma1 trial

MATCHPOINT - Medulloblastoma Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade

Recruiting·UUniversity of Florida·Phase 1·NCT06514898·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for TTRNA-xALT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TTRNA-xALT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TTRNA-xALT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Florida

TTRNA-xALT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Trials by Indication[1]

Glioma2 trials

Oligodendroglioma1 trial

Medulloblastoma1 trial

Recurrent Group 3 Medulloblastoma1 trial

References

Drug Info

Quick Facts

Related News